Flot.bio x Philip Hemme

Why have early AI drug-discovery companies often overpromised but underdelivered? Biology is still complex and hard to solve, Werner told Philip in Vienna.We revisit Werner in Vienna after he left Evotec and went on a sabbatical in 2024. We talk about his new missions as FairJourney CEO and founder of WLAN Holdings, and discuss the global CDMO scene and Europe’s competitivity in biotech.And while it's still early days yet, we find out AI will transform the way we work in biopharma going forward, with new generations of companies shaping their business models around it.⭐️ ABOUT THE SPEAKERWerner is the new CEO of FairJourney Biologics and invests with his holding. He served as CEO of Evotec from 2009 to 2024, expanding the company’s revenues and workforce. Prior to this, he was the CFO of Intercell in Austria for nine years.🔗 LINKS MENTIONEDWLAN Holding’s website - [](https://tiltbio.com/) https://wlanholding.com/Werner Lanthaler, Evotec | Leading AI in Biotech | E02 -- https://flot.bio/episode/werner-lanthaler-evotec-ai-in-biotech/Antoine Papiernik, Sofinnova | Billion Investing with Balance | E01 — https://flot.bio/episode/antoine-papiernik-sofinnova-ebillion-biotech-investing-with-balance/Alex Zhavoronkov, Insilico Medicine | AI Drug Development, Longevity | E39 — https://flot.bio/episode/alex-zhavoronkov-insilico-medicine-ai-drug-development-longevity/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/werner-lanthaler-biopharma-ai/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW USNewsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS[00:00:00] Intro[00:02:09] Werner Lanthaler: from Evotec to new roles[00:06:01] WLAN Holding and the benefits of a sabbatical[00:10:58] Inside the Evotec departure[00:13:13] Joining FairJourney Biologics[00:20:33] The job market in Europe[00:23:49] CDMO competition and China[00:28:07] Letting European biotech compete globally[00:34:50] How AI has overpromised in biopharma[00:48:09] Quick-fire questions

Valneva now has three commercialized vaccines, and a Lyme disease candidate in Phase 3. Philip quizzes CEO Thomas Lingelbach about everything. They also discuss the current political turbulence with vaccines, especially in the US, and how it is impacting the industry.⭐️ ABOUT THE SPEAKERA veteran in the development of more than ten vaccines, Thomas has spent over 30 years in the vaccine space and has served in senior roles at the companies Intercell, Novartis and Chiron. Thomas was with Intercell since 2006 and was the CEO when the company merged with Vivalis to form Valneva in 2013.🔗 LINKS MENTIONEDValneva’s website - https://valneva.com/Valneva’s Half Year 2025 Financial Results - https://valneva.com/press-release/valneva-reports-half-year-2025-financial-results-and-provides-corporate-updates/Lovisa Afzelius, Flagship Pioneering 🇸🇪 | Company building, AI | E24https://flot.bio/episode/lovisa-afzelius-flagship-pioneering/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/thomas-lingelbach-valneva-vaccines/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW USNewsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ Timestamps[00:00:00] Intro[00:03:09] Duck cell vaccines[00:04:55] The grandpa of French and Austrian biotech[00:15:09] Products for chikungunya, Japanese encephalitis and cholera[00:22:04] Valneva and Pfizer’s Lyme disease vaccine[00:29:46] Navigating US anti-vaccine turbulence[00:33:33] The stormy biotech investment market[00:36:32] Thomas Lingelbach talks financials[00:39:46] Quick-fire questions

When Abivax released stunning phase 3 results for ulcerative colitis, its 600% stock price surge froze Euronext for 45 minutes.Philip meets Abivax CEO Marc de Garidel in Vienna, Austria, to go behind the scenes of a remarkable biotech turnaround.Marc discusses the processes involved in executing the phase 3 trial that beat even Abivax’s own phase 2 data. He also talks about France’s biotech ecosystem and the importance of having the right team.⭐️ ABOUT THE SPEAKERMarc de Garidel joined Abivax as CEO in 2023. Prior to this, he led two biotech companies through billion-dollar exits (CinCor Pharma and Corvidia Therapeutics). He also served as CEO of Ipsen from 2010 to 2016, and has worked at the likes of Amgen and Eli Lilly.🔗 LINKS MENTIONEDAbivax’s website - https://www.abivax.com/Phase 3 results - https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week$747.5 million public offering - https://ir.abivax.com/news-releases/news-release-details/abivax-announces-closing-7475-million-public-offeringMarc de Garidel, Abivax | How to make two Billion-dollar exits (“smoothly”) | E09 - https://flot.bio/episode/marc-de-garidel-abivax-exit/Chris Martin, Verona Pharma 🇬🇧 | Ohtuvayre, COPD, Execution | E34 - https://flot.bio/episode/chris-martin-verona-pharma-copd/Christophe Bourdon, LEO Pharma 🇩🇰 | Biopharma Turnaround | E31https://flot.bio/episode/christophe-bourdon-leo-pharma-biopharma/Nanobiotix episode - https://www.youtube.com/watch?v=3Krhyy6a-nw&pp=0gcJCQMKAYcqIYzvFabrice Chouraqui, Pharming 🇳🇱 | Transgenic Rabbits, Rare Diseases | E43 - https://flot.bio/episode/fabrice-chouraqui-pharming-transgenic-rabbit/📜 TRANSCRIPT Read the full transcript here:💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW USNewsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS0:44: Abivax’s crazy Ph3 data and stock price jump4:06: Surging investor demand on NASDAQ and Euronext8:58: Future directions11:02: Executing a Phase 3 home run17:20: Marc de Garidel's leadership style21:58: Abivax: origins34:51: France's billion-dollar biotechs44:11: Quick-fire questions

As Philip travels to France, Nanobiotix CEO Laurent Lévy discusses how the company broke into Europe’s exclusive $1 billion biotech club, alongside the likes of Abivax and Medincell. They also chat about what it means to partner with giants like Johnson & Johnson, and how Laurent’s leadership style has evolved over his long tenure.⭐️ ABOUT THE SPEAKERLaurent Lévy co-founded Nanobiotics in 2003 and has served as CEO ever since. Before this, he worked in a variety of roles with companies including Altran Technologies, Valbiotis and Sanofi.He has a doctorate in nanomaterials-focused physical chemistry from the Pierre and Marie Curie University in Paris.🔗 LINKS MENTIONEDNanobiotix website -- https://nanobiotix.com/Nanobiotix's $71 million deal with Healthcare Royalty -- https://ir.nanobiotix.com/news-releases/news-release-details/nanobiotix-announces-strategic-royalty-monetization-agreementNanobiotix's first phase 1 data -- https://ir.nanobiotix.com/news-releases/news-release-details/nanobiotix-announces-first-data-phase-1-study-evaluating-jnj📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/laurent-levy-nanobiotix-nanoparticles-radiotherapy/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US Newsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS[00:00:00] Intro[00:02:11] Soaring stocks with clinical results[00:04:08] Nanobiotix's history[00:07:39] Nanoparticles and radiotherapy[00:13:42] Developing NBTXR3[00:25:02] Universal cancer radiotherapy enhancers[00:28:28] Few competitors[00:33:37] Biotech in France, Europe and the US[00:37:19] Laurent Lévy’s leadership style[00:42:16] Quick-fire questions

As Philip tours Amsterdam, he visits the biotech tools startup LUMICKS. Founded in 2014, the firm offers products analyzing the binding interactions between molecules and cells, with applications in drug development, CAR-T therapies, and manufacturing.Philip sits down with co-founder Gerrit Sitters to discuss the company’s trajectory, the cyclic biotech investment market, and lessons from spinning the firm out from Vrije Universiteit Amsterdam.---Explore how LUMICKS' technology helps develop biologics and cell therapies with unique cell avidity data — http://bit.ly/lumicks---⭐️ ABOUT THE SPEAKERGerrit co-founded LUMICKS in 2014 following a PhD at Vrije Universiteit Amsterdam, and co-invented the technology behind LUMICKS’ main products. Gerrit now serves as Head of Product, where he aims to deploy the company’s products to tackle challenges in the life sciences.🔗 LINKS MENTIONEDLUMICKS’ website - https://www.lumicks.com/NanoTemper: https://flot.bio/episode/philipp-baaske-nanotemper-boostrapping-biotech/DNA Script: https://flot.bio/episode/thomas-ybert-dna-script-dna-printing/Adaptimmune: https://flot.bio/episode/adrian-rawcliffe-adaptimmune/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/gerrit-sitters-lumicks-car-t-therapy/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW USNewsletter: http://eepurl.com/h_fnmHLinkedIn: https://www.linkedin.com/company/flot-bio/X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS[00:00:00] Intro[00:02:09] The history of LUMICKS[00:08:33] Visualizing microscopic interactions[00:14:29] Improving drug development[00:20:33] AI and digital labs[00:29:53] Quality control and manufacturing applications[00:31:58] Single-cell analysis and CAR-T[00:46:13] LUMICKS’ future milestones[00:47:13] Cyclic biotech market[01:00:15] Gerrit Sitters’ career takeaways[01:18:01] Quick-fire questions

We travel to the offices of Pharming Group in Leiden, the Netherlands, to chat with the newcomer CEO Fabrice Chouraqui.Fabrice discusses the fascinating history of Pharming, with its first commercial drug RUCONEST produced in the milk of transgenic rabbits. He also talks about the growth of Pharming from a protein therapy-focused biotech into a European multi-asset heavyweight, with a market cap of at least €800 million. ⭐️ ABOUT THE SPEAKERFabrice Chouraqui has been the CEO of Pharming Group since March 2024. Prior to this, he was a CEO-Partner at the US biotech venture capital firm Flagship Pioneering as well as CEO of the Flagship portfolio company Cellarity.He also served at Novartis and Bristol-Myers-Squibb for 10 years each, with his career beginning in R&D at pharmaceutical companies that were predecessors to today’s Sanofi. 🔗 LINKS MENTIONED- Pharming Group’s website - https://www.pharming.com/- Pharming Group’s second quarter and first half 2025 financial results - [https://www.pharming.com/sites/default/files/imce/Presentations/Pharming 2Q25_1H 2025 presentation_31JUL2025_website.pdf](https://www.pharming.com/sites/default/files/imce/Presentations/Pharming%202Q25_1H%202025%20presentation_31JUL2025_website.pdf)- Stefano Portolano, Azafaros 🇳🇱 🇨🇭 | Rare Diseases, Small Molecules | E40 -https://flot.bio/episode/stefano-portolano-azafaros-rare-disease/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/fabrice-chouraqui-pharming-transgenic-rabbit/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS- [00:00:00] Intro- [00:02:12] Kicking off at Pharming- [00:04:26] RUCONEST and transgenic rabbits- [00:06:57] Path to profitability- [00:13:43] Encouraging stock price trends- [00:17:39] The protein and small molecules portfolio- [00:28:13] Switching gear to commercialization - [00:33:40] European biotech success stories- [00:39:55] Lessons from Fabrice Chouraqui’s career- [00:47:29] Quick-fire questions

Hot on the heels of CUTISS’ $60M Series C round, we catch up once more with CEO and co-founder Daniela Marino. We chat about the company’s mission to develop an engineered tissue therapy to reduce the need for skin grafts in patients with severe burns. She also explains the decentralization of tissue manufacturing with automation and the need for perseverance as a founder and CEO.---This episode is sponsored by CUTISS, the only TechBio company in the advanced clinical stage of developing skin tissue therapies. Learn how you can support CUTISS on its path to Series C success: https://bit.ly/flotbio-cutiss---⭐️ ABOUT THE SPEAKERIn 2023, Daniela Marino was named as one of the 30 Rising Leaders in the healthcare industry, thanks to the impact of CUTISS, the company she co-founded as a spin-off from the University of Zurich. Here, she and her team have made waves for people suffering from severe skin injuries and defects through regenerative medicine, tissue engineering, and skin pigmentation.🔗 LINKS MENTIONED- CUTISS’ website – https://cutiss.swiss/- CUTISS’ Series C round – https://cutiss.swiss/cutiss-closes-chf-56m-series-c-round-and-signs-agreement-with-leading-european-burn-center/- CUTISS’ Phase II trial data – https://cutiss.swiss/phase-2-clinical-trials-update-from-cutiss/- Daniela Marino, CUTISS 🇨🇭 | Skin Tissue Therapeutics, TechBio | E33 – https://flot.bio/episode/daniela-marino-cutiss-skin-tissue-therapeutics/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/daniela-marino-cutiss-tissue-engineering/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW USNewsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS[00:00:00] Intro- [00:02:31] Investors in CUTISS’ Series C round [00:06:45] Expanding a hospital collaboration [00:08:34] Decentralized manufacturing drive [00:11:50] Tissue therapeutics vs skin grafts [00:24:35] Reimbursement and health economics [00:38:39] CUTISS’ partnering and exit options [00:47:54] Automation and artificial intelligence [00:56:32] Europe can show its strength in biotech [00:58:52] Daniela Marino answers quick-fire questions

Philip meets up with Dragan Grabulovski, CEO of the startup Araris, at Lake Zurich to chat about the company’s work with antibody-drug conjugates (ADCs).They talk about Araris’ huge $400M upfront buyout by Taiho Pharma of Japan, Dragan’s extensive history as a biotech entrepreneur, and Araris’ vision to replace chemotherapy with ADCs.⭐️ ABOUT THE SPEAKERDragan Grabulovski is a co-founder of the startup Araris and became CEO in 2023. He previously worked as a biotech consultant and startup coach in Switzerland. He co-founded the biotech company Covagen in 2007, which was acquired by Johnson & Johnson in 2014. Dragan has a Master’s degree and a PhD in Pharmaceutical Sciences from ETH Zurich.🔗 LINKS MENTIONED- Araris’ website: https://www.ararisbiotech.com/- Taiho Pharma acquires Araris: https://www.ararisbiotech.com/docs/250316_250317-araris-taiho-pr.pdf- Robin Carr, Myricx Bio 🇬🇧 | New ADC Payloads, London Biotech Startups | E38: https://flot.bio/episode/robin-carr-myricx-bio-adc/- Dominik Schumacher, Tubulis 🇩🇪 | Founder-led ADC Biotech ⭐️ | E19: https://flot.bio/episode/dominik-schumacher-tubulis/- ETH entrepreneurship and terms: https://ethz.ch/staffnet/en/news-and-events/internal-news/archive/2025/07/new-business-creation-regulations-and-equity-and-licensing-policy.html 📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/dragan-grabulovski-araris-adc/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 25k monthly views. Free.⏰ TIMESTAMPS- [00:00:00] Intro- [00:02:08] Araris’ acquisition by Taiho Pharma- [00:08:29] Covagen: Dragan Grabulovski’s first exit- [00:12:54] The origins of Araris and its ADC tech- [00:22:14] How to value a technology platform - [00:29:34] The burgeoning ADC market- [00:41:53] ADCs replacing chemotherapy- [00:46:15] The Swiss biotech ecosystem- [01:00:53] Quickfire questions

On a trip to Basel, Switzerland, Philip catches up with Stefano Portolano, CEO of the European firm Azafaros. They chat about Azafaros’ massive $147M Series B round in May 2025, which is being used to develop a small molecule treatment for rare diseases known as lysosomal storage disorders.Stefano also explains how rare diseases went in and out of fashion with big pharma, the revival of small molecule drugs relative to gene therapies and biologics, and his extensive experience in big biotech firms.⭐️ ABOUT THE SPEAKERWith more than 20 years of experience in orphan diseases under his belt, Stefano Portolano joined Azafaros in 2021. He previously served as Vice President, Strategy & Commercial Operations at Celgene and Head of Europe at Ultragenyx Pharmaceuticals.Stefano first received his Doctor of Medicine from Università degli Studi di Napoli ‘Federico II,’ Italy and carried out research in autoimmunity as an adjunct assistant professor of Medicine at the University of California, San Francisco, USA.🔗 LINKS MENTIONED- Azafaros website - https://www.azafaros.com/- Azafaros Series B round - https://www.azafaros.com/news/azafaros-secures-132m-in-oversubscribed-series-b-financing-to-advance-phase-3-clinical-programs-of-innovative-therapies-in-lysosomal-storage-disorders/l211c14- Joris Pezzini, Alira Health | Hottest Biotech Insights - https://flot.bio/episode/joris-pezzini-alira-health-biotech-trend/- Marc de Garidel, Abivax | How to make two Billion-dollar exits (“smoothly”) - https://flot.bio/episode/marc-de-garidel-abivax-exit/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/stefano-portolano-azafaros-rare-disease/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 20k monthly views. Free.⏰ TIMESTAMPS- [00:00:00] Intro- [00:01:45] Azafaros’ origin and $147M B round- [00:04:39] Developing nizubaglustat- [00:11:17] Competition in Niemann-Pick disease type C- [00:18:44] The small molecule revival- [00:24:29] Keeping options open- [00:27:23] Europe’s growing role in biotech investments- [00:30:12] The rare disease fashion- [00:51:20] Getting personal with Stefano Portolano- [01:11:11] Quickfire

Alex Zhavoronkov, CEO of Insilico Medicine, discusses the game-changing role of AI in drug discovery and its potential impact on longevity. He shares insights into Insilico's impressive pipeline and the challenges faced by longevity startups. Alex emphasizes the importance of developing demonstrable benchmarks and the shift towards creating in-house assets. With a bold vision for manipulating aging, he advocates for increased investments in this field to drive innovation and breakthroughs.